- Facebook Fiasco: 10 Things Underwriters Got Wrong
- Sticker Shock: What College Is Likely to Cost in 18 Years
- What Happened to Stocks? Most Unloved in 50 Years
- Icahn Raises Stake in Chesapeake, Wants Board Seats
- Citigroup Lost $20 Million on Facebook IPO Trades
- Break Up JPMorgan: Sheila Bair
- Main Players in the Greek Election
- Many Greeks Moved Their Money Abroad Long Ago
- Bankia Asks Spain for $24 Billion Bailout
- A New Look at the ‘New Poor’
- Six Pack: Beer Buzz of the Week
- Greek Exit Could Trigger 50% Fall in Euro Stocks: Analyst
- Under Pressure, FHA Skews to Wealthier Home Buyers
- Big Stock Upside for Hudson City Deal: Analyst
- 5 High-Yield Stocks Ready to Boost Dividends
- Yoshikami: Four Things You Need to Know About Gold Now
- Steinbock: The Euro Zone Endgame Begins
- Option Bulls Take Another Shot on Idenix
MOST SHARED
- Citigroup Lost $20 Million on Facebook IPO Trades
- Oil Declines, but Doesn't Help European Consumers
- Traders Worry Over 'Possible Risks' During Long Weekend
- Bankia Asks Spain for $23 Billion Bailout
- Spanish Lender Seeks 19 Billion Euros; Ratings Cut on 5 Banks
- Najarian: Yahoo! a Must Own Stock
- Facebook: The Song — Yes, We're Serious
- Marc Faber: 100% Chance of Global Recession
- S&P Cuts Ratings on Five Spanish Banks
- The Shortage of Women Billionaires
MOST POPULAR
HOT ON FACEBOOK
CV Therapeutics Angina Drug Not Effective in Study; Shares Plunge
Text Size 
Shares of CV Therapeutics plummeted [CVTX
Loading...
()
] following the company's announcement late Tuesday that its angina drug ranolazine was not effective in a study of acute and long-term treatment of patients with a type of heart disease known as acute coronary syndrome.
Wednesday's drop came on top of the shares losing more than a quarter of their value in after-market trading Tuesday.
There was no adverse trend in death or arrhythmias in patients taking the drug, also known by the chemical name ranolazine, the company said.
CV Therapeutics said it believes the data could support expansion of the drug's approved uses to be included as a first choice treatment for angina. It is currently approved to treat chronic angina in patients who have not achieved an adequate response with other drugs.
- The Nasdaq has suffered the most from the EU crisis showing there's risk in the usual tech stocks.
- Targeting more Millennials is just one of the items brewing for consumers in the world of spirits.
- It seems many people may need a reminder of how NOT to act on a plane. Here are a few tips.
- Here are some very unusual roadside stops along American highways that might peek your interest.
- How three generations of Americans are dealing with the finances of retirement.
Data is a real-time snapshot *Data is delayed at least 15 minutes
